The role of adenosine in insulin-induced vasodilation.
It was previously shown that systemic hyperinsulinemia induces vasodilation in human skeletal muscle. The mechanism mediating this vasodilation is not yet completely clarified. Based on data from animal experiments, we hypothesized that stimulation of the adenosine receptor is involved in insulin-induced vasodilation. To test this hypothesis, a 105-min hyperinsulinemic euglycemic clamp was performed in three groups of eight healthy volunteers. In group 1, placebo was infused into the left brachial artery (experimental forearm). In the second and third group, respectively, draflazine (an adenosine-uptake blocker) and theophylline (an adenosine-receptor antagonist) were administered by intrabrachial infusion. Forearm blood flow (FBF) was measured by venous-occlusion plethysmography, both at the experimental and the control forearms. The percentage decrease in flow ratio (FBF experimental arm/control arm) in the draflazine group was significantly less pronounced than that in the placebo group, whereas the percentage decrease in flow ratio was larger in the theophylline group. These results demonstrate that the insulin-induced increase in blood flow in the experimental arm was more pronounced at the site of adenosine-uptake blockade by draflazine, whereas this was reduced during adenosine-receptor antagonism by theophylline. Our observations are compatible with the hypothesis that insulin-induced vasodilation is mediated by the release of adenosine.
Abbink-Zandbergen
E J
EJ
Department of Internal Medicine, University Hospital Nijmegen, The Netherlands. E.Abbink@aig.azn.nl
Vervoort
G
G
Tack
C J
CJ
Lutterman
J A
JA
Schaper
N C
NC
Smits
P
P
D000241:Adenosine / Q000008:administration & dosage / Q000502:physiology*; D000293:Adolescent; D000328:Adult; D000704:Analysis of Variance; D005542:Forearm / Q000098:blood supply; D006801:Humans; D007328:Insulin / Q000502:physiology*; D010879:Piperazines / Q000494:pharmacology; D010975:Platelet Aggregation Inhibitors / Q000494:pharmacology; D058915:Purinergic P1 Receptor Antagonists; D018047:Receptors, Purinergic P1 / Q000502:physiology*; D012039:Regional Blood Flow; D013806:Theophylline / Q000494:pharmacology; D014655:Vascular Resistance; D014664:Vasodilation / Q000502:physiology*; D014665:Vasodilator Agents / Q000494:pharmacology
D007328:Insulin; D010879:Piperazines; D010975:Platelet Aggregation Inhibitors; D058915:Purinergic P1 Receptor Antagonists; D018047:Receptors, Purinergic P1; D014665:Vasodilator Agents; C072040:draflazine; D013806:Theophylline; D000241:Adenosine